Article Text

Download PDFPDF
EP884 Synchronous primary carcinoma in left tubal carcinosarcoma and right tubal serous carcinoma: a case report
  1. NR Kim1,
  2. SH Chae1,
  3. S-H Shim1,
  4. KA So1,
  5. SJ Lee1 and
  6. S-B Kang2
  1. 1Konkuk University Medical Center
  2. 2Hosan Women’s Hospital, Seoul, Republic of Korea


Introduction/Background Synchronous primary carcinoma of the female genital tract is relative rare cancerous condition. Although the etiology of this cancerous condition is unclear, some postulated that the extended mullerian system comprising the ovarian epithelium, fallopian tube, uterine corpus, and cervix, may respond as a single morphologic unit to produce primary carcinomas in multiple sites. Endometrium and ovary are common sites for coexistence of primary cancers. However, there is no data about adnexa cancers in different pathology. We will introduce synchronous primary carcinoma in different pathology in both adnexa.

Methodology Case report.

Results Pelvic-abdomen CT announced large multilocular solid mass in left adnexa which should be rule out for malignant epithelial ovarian cancer with peritoneal seeding. Pelvic MRI showed 7 cm sized large solid mass in left adnexa which is also diagnosed as malignant epithelia ovarian cancer. On October, 17th, 2017 Cytoreductive operation (Peritoneal washing, hysterectomy, bilateral salpingo-Oophorectomy, pelvic lymph node dissection, para-aortic lymph node dissection, peritoneal mass excision, total omentectomy, appendectomy, diaphragm biopsy) in midline incision from xyphoid process to pubic bone was done. The uterus was atrophied, the right adnexa had small cancerous mass, and the left adnexa had 5 cm papillos cancerous mass. The left adnexa done frozen biopsy and serous cancer was diagnosed. The pathology was reported that the patients might be double primary cancer. One is 13 × 12 × 2 cm sized left carcinosarcoma which is origin from left fimbria or salpinx and the other is 0.3 × 0.3 × 0.3 cm right serous carcinoma origin from right fimbria.She stated the first chemotherapy on November, 7th, 2017 with paclitaxel (BSA × 175) and carboplatin (AUC × 5) 3weeks regimen.

Conclusion Synchronous primary carcinoma is very rare and not much studies are existed. This paper will give some information.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.